[go: up one dir, main page]

WO2010015586A3 - 2,3,4,7-tetrahydro-indolo[2,3-c]quinoline compounds - Google Patents

2,3,4,7-tetrahydro-indolo[2,3-c]quinoline compounds Download PDF

Info

Publication number
WO2010015586A3
WO2010015586A3 PCT/EP2009/059999 EP2009059999W WO2010015586A3 WO 2010015586 A3 WO2010015586 A3 WO 2010015586A3 EP 2009059999 W EP2009059999 W EP 2009059999W WO 2010015586 A3 WO2010015586 A3 WO 2010015586A3
Authority
WO
WIPO (PCT)
Prior art keywords
indolo
tetrahydro
quinoline compounds
invention pertains
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2009/059999
Other languages
French (fr)
Other versions
WO2010015586A2 (en
Inventor
Björn BARTELS
Steffen Weinbrenner
Degenhard Marx
Jörg DIEFENBACH
Torsten Dunkern
Wiro M.P.B. Menge
Johannes A. M. Christiaans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Nycomed GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed GmbH filed Critical Nycomed GmbH
Publication of WO2010015586A2 publication Critical patent/WO2010015586A2/en
Publication of WO2010015586A3 publication Critical patent/WO2010015586A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention pertains to 2,3,4,7-tetrahydro-indolo[2,3-c]quinoline compounds, as well as the resulting pharmaceutical compositions, and their use in the treatment or prophylaxis of diseases alleviated by inhibition of type 5 phosphodiesterases. Furthermore, the present invention pertains to the methods of manufacturing these 2,3,4,7-tetrahydro-indolo[2,3-c]quinoline compounds.
PCT/EP2009/059999 2008-08-05 2009-08-03 2,3,4,7-tetrahydro-indolo[2,3-c]quinoline compounds Ceased WO2010015586A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08161789 2008-08-05
EP08161789.6 2008-08-05

Publications (2)

Publication Number Publication Date
WO2010015586A2 WO2010015586A2 (en) 2010-02-11
WO2010015586A3 true WO2010015586A3 (en) 2010-07-22

Family

ID=40029596

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/059999 Ceased WO2010015586A2 (en) 2008-08-05 2009-08-03 2,3,4,7-tetrahydro-indolo[2,3-c]quinoline compounds

Country Status (1)

Country Link
WO (1) WO2010015586A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4014883A (en) * 1973-09-10 1977-03-29 Hoffmann-La Roche Inc. Indoloquinolines, intermediates and processes
SU753093A1 (en) * 1979-03-05 1982-11-30 Институт физико-органической химии и углехимии АН УССР 1-methyl-3,4-(delta 2,2-dimethyl-4-oxotetrahydrobenzo)-tranquilizing activity
WO2002064590A2 (en) * 2001-02-12 2002-08-22 Lilly Icos Llc Carboline derivatives
US20080051426A1 (en) * 2006-08-28 2008-02-28 Irina Shcherbakova Indoloquinoline compounds as calcium channel blockers
EP1953159A1 (en) * 2007-02-05 2008-08-06 Nycomed GmbH 6-Benzyl-2,3,4,7-tetrahydro-indolo[2,3-c]quinoline compounds useful as PDE5 inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4014883A (en) * 1973-09-10 1977-03-29 Hoffmann-La Roche Inc. Indoloquinolines, intermediates and processes
SU753093A1 (en) * 1979-03-05 1982-11-30 Институт физико-органической химии и углехимии АН УССР 1-methyl-3,4-(delta 2,2-dimethyl-4-oxotetrahydrobenzo)-tranquilizing activity
WO2002064590A2 (en) * 2001-02-12 2002-08-22 Lilly Icos Llc Carboline derivatives
US20080051426A1 (en) * 2006-08-28 2008-02-28 Irina Shcherbakova Indoloquinoline compounds as calcium channel blockers
WO2008027182A2 (en) * 2006-08-28 2008-03-06 Medipropharma, Inc. Indoloquinoline compounds as calcium channel blockers
EP1953159A1 (en) * 2007-02-05 2008-08-06 Nycomed GmbH 6-Benzyl-2,3,4,7-tetrahydro-indolo[2,3-c]quinoline compounds useful as PDE5 inhibitors

Also Published As

Publication number Publication date
WO2010015586A2 (en) 2010-02-11

Similar Documents

Publication Publication Date Title
WO2008006547A3 (en) Pyrrolopyrimidines for pharmaceutical compositions
WO2008104306A3 (en) Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
SG179120A1 (en) Novel compounds
WO2007058602A3 (en) Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia.
WO2011014795A3 (en) Compounds and compositions as syk kinase inhibitors
WO2008115974A3 (en) Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
WO2009127642A3 (en) Use of lrrk2 inhibitors for neurodegenerative diseases
WO2012162254A8 (en) Inhibitors of lrrk2 kinase activity
WO2008079291A3 (en) Substituted heterocycles and methods of use
WO2010108074A3 (en) Inhibitors of pi3 kinase
WO2010057101A3 (en) Compounds useful as hiv blockers
WO2006106326A8 (en) Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2008094992A3 (en) 2-aminopyridine derivatives useful as kinase inhibitors
WO2010011772A3 (en) Tri-cyclic pyrazolopyridine kinase inhibitors
WO2012016186A8 (en) Macrocyclic kinase inhibitors and uses thereof
IN2014DN07384A (en)
WO2012046030A3 (en) Phosphodiesterase inhibitors
WO2008149353A3 (en) Telomerase activating compounds and methods of use thereof
WO2006066937A3 (en) Mnk1 or mnk2 inhibitors
WO2007109279A3 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
WO2012048129A3 (en) Inhibitors of polo-like kinase
WO2007059905A3 (en) Thienopyrimidines treating inflammatory diseases
WO2007093880A3 (en) Novel pyrone-indole derivatives and process for their preparation
WO2010014253A3 (en) Ant4 inhibitor compounds and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09781396

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09781396

Country of ref document: EP

Kind code of ref document: A2